Specialty chemicals company LANXESS is pursuing additional cost reductions and portfolio adjustments, expecting €170 million in further savings through 2028 from its FORWARD! program. The company reported Q2 EBITDA pre of €152 million, up from €94 million in Q1, and maintained its full-year 2026 EBITDA pre guidance at €450 million to €550 million. LANXESS aims to reduce net debt below 2.5 times EBITDA and restore investment-grade status, partly by monetizing its Envalior stake.